WALTHAM, Mass. and BOULDER, Colo., March 07, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its participation in a …
VANCOUVER, British Columbia and WILMINGTON, Mass., March 07, 2025 (GLOBE NEWSWIRE) -- Liberty Defense Holdings Ltd. (“Liberty” or the “Company”) (TSXV: SCAN, OTCQB: LDDFF, FSE:E30) a leading technology provider of AI-based next generation detection …
BEDFORD, Mass., March 07, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the Osteoarthritis Pain Management and Regenerative Solutions space focused on early intervention orthopedics, today announced the completion of …
Recognized for Excellence in Sales Recruitment at the 2025 Stevie Awards WAKEFIELD, MA, UNITED STATES, March 6, 2025 /EINPresswire.com/ -- Treeline, Inc. is proud to announce that it has won the Gold Stevie Award for Sales Recruitment …
BOSTON, MA, UNITED STATES, March 6, 2025 /EINPresswire.com/ -- Long-time radio personality Frankie Boyer, beloved host of the Holistic Health Show on WCRN 830 AM (Boston/Worcester), and lifestyle shows on WADK 1540 AM (Newport, RI), WGCH 1490 …
BOSTON, MA, UNITED STATES, March 6, 2025 /EINPresswire.com/ -- Adeel Shams, co-founder of the globally renowned streetwear powerhouse CoolKicks, and Lena, the visionary force behind GoldPawnership, a premier purveyor of authentic luxury designer …
Cisco, IBM, Intel, Microsoft, Red Hat, and Others Unite to Promote Cross-Industry Standards for Traditional Data and AI Applications BOSTON, MA, UNITED STATES, March 6, 2025 /EINPresswire.com/ -- OASIS Open, a global open source and standards …
- Topline-Zwischendatensatz von GALAXIES Lung-201 mit >240 Patienten für das 2. Quartal 2025 erwartet - Zwischendatensätze von GALAXIES H&N-202 und TIG-006 HNSCC mit ~200 Patienten für 2025 erwartet - Abgeschlossene Rekrutierung der zweiten Dosis- …
- Données provisoires de haut niveau issues de l’étude GALAXIES Lung-201 portant sur plus de 240 patients prévues pour le 2ᵉ trimestre 2025 - Données provisoires de l’étude GALAXIES H&N-202 et TIG-006 HNSCC portant sur ~200 patients prévues en 2025 - …
Can a Simple 3 x 4 Framework Unlock the Secrets to Goals, Values, Culture, Engagement, Leadership, and Team Effectiveness? BOSTON, MA, UNITED STATES, March 6, 2025 /EINPresswire.com/ -- Dr. J.D. Pincus, a leading researcher in motivation and …
Adroit DI adds Steve Herbert as an Advisor & Board Member. His tech/commercial expertise will drive data management innovation. BOSTON, MA, UNITED STATES, March 6, 2025 /EINPresswire.com/ -- Adroit DI, a leading life sciences data …
SPRINGFIELD, MA, UNITED STATES, March 6, 2025 /EINPresswire.com/ -- The Choroideremia Research Foundation (CRF) is excited to announce the 2025 CRF International Conference, taking place June 25 – 28, 2025, at the Radisson Blu Mall of America in …
Track Title: Jerusalem Genre: Pop / Alternative Launch Date: 1st March 2025 ISRC Code: QZES62579015 BOSTON, MA, UNITED STATES, March 6, 2025 /EINPresswire.com/ -- Passionate about bridging the often solitary world of depression and emotional …
- Duchenne: Reported positive initial data from INSPIRE DUCHENNE trial of next-generation Duchenne gene therapy candidate, SGT-003; In mid-2025, Company plans to request a U.S. Food and Drug Administration (FDA) meeting to discuss potential accelerated …
First-in-class oral selective SMARCA2 (BRM) inhibitor FHD-909 (LY4050784) continues enrollment in Phase 1 trial for SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population FHD-909 preclinical combination …
Successful End-of-Phase 2 Meeting with FDA and Alignment on Phase 3 Program for Hepatitis C Virus (HCV) Patient Enrollment in Global Phase 3 HCV Program Expected to Start in April 2025 Conference Call at 4:30 pm ET Today BOSTON, March 06, 2025 (GLOBE …
Clinical data on track for Q2 2025 in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC Expansion of investigator sponsored “window of opportunity” trial into newly diagnosed glioblastoma patients with EGFR aberrations expected in Q1 …
FDA approves scPharmaceuticals’ supplemental New Drug Application to expand the FUROSCIX indication to include the treatment of edema in adult patients with chronic kidney disease, including nephrotic syndrome FUROSCIX is expected to be available for …
DLL3 targeting Radio-DARPin MP0712 to enter first-in-human study in 2025, pending regulatory clearance Strategic partnership with Orano Med on Radio-DARPins now expanded to ten programs MP0533 Phase 1/2a clinical data show improved response rate and …
SPRINGFIELD, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- LLumin, the leading CMMS (computerized maintenance management system) provider, announces it has been recognized in ARC Advisory Group’s insightful piece regarding the best way to handle assets and …
